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Simple Summary: Kidney cancer occurs more commonly within the general population and has
historically been associated with morbidity and early death. The most common form of kidney cancer
is clear cell renal cell carcinoma. Thankfully, there now have multiple new therapies available for
patients with metastatic disease that are improving the lives of patients. However, the number of
new drugs and treatment types has created a degree of complexity in treatment planning. We review
the most recent data in the metastatic disease space surrounding treatment for patients with newly
diagnosed metastatic clear cell renal cell carcinoma. These treatments include surgery, radiation, and
systemic therapies. Current systemic therapies include drugs that activate the immune system to
target cancer cells and small-molecule drugs that target a cancer cell’s ability to grow and survive.
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Abstract: The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved over the
years, and we are now in an era of combination therapy strategies employing immune checkpoint
blockade and anti-angiogenesis targeted therapy. Since 2018, we have gained regulatory approval for
four distinct combination therapies, all with survival benefits, and with guideline recommendation
for use in the front-line setting. As such, treatment selection has become increasingly complex with
a myriad of treatment choices but little high-level head-to-head data to guide treatment selection.
Heterogeneity in tumor biology further complicates treatment selection as tumors vary in behavior
and treatment responsiveness. Ongoing development of biomarkers will certainly assist in this
setting, and validation of predictive markers represents an unmet need. In their absence, we highlight
features of disease and nuances to datasets from landmark prospective clinical trials to help inform
treatment selection. There is growing evidence to support deferring upfront systemic therapy in some
patients, with opportunities for active surveillance or metastasis-directed therapy. In others, upfront
systemic therapy is warranted and necessitates thoughtful consideration of multiple clinicopathologic
parameters to inform optimal patient-centered decision making.
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1. Introduction
Renal cell carcinoma (RCC) is the eighth most common malignancy in the United
States, with an annual incidence on the rise [1]. RCC is a biologically diverse tumor with
varying drivers of tumorigenesis, and with >75% of tumors being clear cell in histology.
Advanced disease had been traditionally associated with morbidity and early mortality
as tumors proved resistant to conventional radiotherapy, hormonal therapy, and cytotoxic chemotherapy. Prior to 2005, the mainstays of therapy were high-dose interleukin-2
(HDIL-2) and interferon-alpha (IFN-α). In this setting, treatment toxicities were abundant
and outcomes were generally poor with durable responses observed in the minority of patients. However, over the last 20 years we have observed a paradigm shift in the treatment
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of metastatic RCC (mRCC) with the emergence of novel therapeutic approaches that have
dramatically improved survival [2].
The discovery of the von Hippel–Lindau (VHL) tumor suppressor gene, and its ubiquitous loss of function in clear cell disease has improved our understanding of the underlying
molecular drivers of RCC. VHL encodes for the substrate of the ligase that targets hypoxiainducible factor (HIF) for destruction in the presence of oxygen [3]. When function is
aberrant, there is unregulated expression of vascular endothelial growth factor (VEGF) and
its downstream signaling cascade. This leads to unregulated cell growth, angiogenesis, and
tumor cell invasion [4]. Targeting this pathway has served as a therapeutic strategy and has
allowed for a ‘revolution’ in drug development for mRCC with multiple targeted therapies
available that have improved survival.
Capitalizing on the immunogenicity of RCC, and based on prior success with HDIL-2
and IFN-α, we witnessed a second ‘revolution’ in the mRCC treatment paradigm with
the advent of immune checkpoint blockade (ICB). ICB includes agents targeting cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and
programmed death-1 ligand 1 (PD-L1). Immuno-oncology (IO)-based strategies are now
employed in the front-line setting for mRCC. Patient outcomes continue to improve and
there has been a dramatic shift in median survival from being <1 year in the 1990s to over
4 years in most recent trials [5].
These successes have led to approvals in consecutive years of a number of agents as
monotherapy or in combination strategies. The rapid rate of discovery and drug development for mRCC has led to approval of a myriad of treatment options that has created a
degree of complexity that has yet to be reconciled in the literature. We now have United
States Food and Drug Administration (FDA) approval and guideline recommendation for
four combination therapies in the front-line setting (Table 1). Cross-trial comparisons are
a challenge here, as the major studies employ varying end points, statistical strategies,
and populations. We provide an overview of the data supporting a variety of treatment
approaches, and highlight nuances that may assist in clinical decision making.
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Table 1. Front-line approaches to metastatic RCC avoiding immediate initiation of systemic therapy.
Active Surveillance
Study

Study Setting
(sample size)

Patient population and characteristics

Median follow-up

Derived benefit
(months)

38.1 months

Median time on AS 14.9 m
(95% CI, 10.6–25.0)
Median OS from start of surveillance 44.5 m
(95% CI, 37.6 m-NR)

33.0 months

Median OS was NR
(95% CI, 122 months—NE)
Kaplan–Meier estimate for living at 3 years: 84%

Median Follow-up

Derived benefit
(months)

50.9 months

Median OS (95% CI) Upfront CN: 15.6 m (95% CI,
12.5–18.6)
Median OS sunitinib alone: 19.8 m (95% CI,
15.6–24.8)
HR 0.97 (0.79–1.19)

3.3 years

Median OS upfront CN: 15.0 m (95% CI, 9.3–29.5)
Median OS upfront sunitinib: 32.4 m (95% CI,
14.5–65.3)
HR 0.57 (0.34–0.95)

Median Follow-up

Derived benefit
(months)

Treatment-naive, asymptomatic, metastatic
RCC.
Rini et al. [6]

Prospective phase II trial
(n = 52)

-

75% IMDC intermediate risk
98% prior nephrectomy
83% ≤ 2 sites of metastases

Treatment-naïve metastatic RCC
MaRCC trial [7]

Prospective observational study
(n = 504, 143 on AS)

-

38% IMDC intermediate risk
58% prior nephrectomy
92% ≤ 2 sites of metastases
Cytoreductive Nephrectomy

Study

Study setting
(sample size)

Trial design

CARMENA [8]

Randomized phase III,
non-inferiority trial of clear cell RCC
(n = 576)
MSKCC poor risk 43%

Nephrectomy followed by sunitinib
vs.
Receive sunitinib alone

SURTIME [9]

Randomized phase III, superiority
trial of clear cell RCC
(n = 458)
MSKCC poor risk 11%

Immediate CN followed by sunitinib
vs.
Treatment with 3 cycles of sunitinib followed
by CN
Metastasis-Directed Therapy

Study

Study setting
(sample size)

Study design
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Table 1. Cont.
Active Surveillance

SBRT [10]

Single-arm Phase II trial of
metastatic clear cell RCC with ≤5
sites of metastases and prior
nephrectomy
(n = 30)

Treatment with SBRT (defined as ≤5 fractions
with ≥7 Gy per fraction) to all lesions and
maintained off systemic therapy

Metastasectomy
[11]

Observational study of registry
patients who underwent partial or
radical nephrectomy with
occurrence of metastasis treated
with complete metastasectomy
(n = 403, 147 with complete
metastasectomy)

Associations of complete metastasectomy with
cancer specific and OS were assessed in the era
of TKI and ICB

17.5 months

Median PFS survival was 22.7 months (95% CI,
10.4–NR)
1-year PFS 64% (95% CI, 48–85)

3.9 years

Two-year cancer-specific survival was significantly
greater in patients with vs. without complete
metastasectomy (84% vs. 54%, p < 0.001)
HR for death from RCC 0.47 (95% CI, 0.34–0.65,
p < 0.001)

IMDC, International Metastatic RCC Database Consortium; RCC, renal cell carcinoma; AS, active surveillance; OS, overall survival; NR, not reached; NE, not evaluable; CN, cytoreductive
nephrectomy; MSKCC, Memorial Sloan Kettering Cancer Center; SBRT, stereotactic body radiotherapy; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; ICB, immune
checkpoint blockade.
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2. Risk Stratification to Guide Management
Prior to considering systemic therapy, applying clinically validated tools to risk stratify
the patient’s disease is recommended. The International Metastatic RCC Database Consortium (IMDC) criteria are a validated prognostic model, which categorizes patients by risk of
early cancer mortality (three risk groups: favorable, intermediate, or poor) [12]. The IMDC
criteria consists of 6 clinical parameters; anemia, thrombocytosis, Karnofksy performance
status, hypercalcemia, neutrophilia, and time from diagnosis to initiation of systemic therapy. Nearly 80% of patients encountered in clinical practice have IMDC intermediate- or
poor-risk disease [13]. Many of the landmark trials that inform guideline recommendations
integrated the IMDC risk model into cohort assignment as well as statistical analyses. As
such, accounting for IMDC risk is necessary for applying standard-of-care therapy.
The IMDC criteria was designed during the development of anti-VEGF targeted therapies. As such, its value nests in the angiogenesis-driven biology of RCC tumors. Now in
the contemporary era of IO, the criteria continue to demonstrate prognostic and predictive
value and it is believed that the criteria reflect the multifaceted underlying biology within
the RCC tumor microenvironment and that they remain applicable [14,15]. Ongoing studies are integrating markers of immunogenicity and genomics into risk stratification [16,17],
but these have not yet been incorporated into standard practice recommendations.
3. Deferring Initiation of Systemic Therapy
3.1. Active Surveillance
There is a growing body of evidence supporting the use of active surveillance (AS)
in select patients with metastatic disease. In patients with indolent growth and who are
asymptomatic from tumor burden, AS provides an opportunity for a prolonged toxicity-free
interval without compromising survival. This was formally investigated in a prospective
phase II trial, which enrolled 52 treatment-naïve, asymptomatic patients with mRCC.
Patients were followed radiographically until initiation of systemic therapy, the timing
of which was at the discretion of the treating physician and patient [6]. At a median
follow-up time of 38.1 months, the median time of surveillance was 14.9 months. The trial
investigators performed a subset analysis whereby the study population was partitioned
into a favorable group (0–1 IMDC risk factor and ≤2 metastases) and an unfavorable
group (IMDC 2–6 risk factors, >3 metastases). The favorable group had a remarkable
median surveillance time of 22.2 months (95% CI, 13.8–33.3) compared to 8.4 months
(3.2–14.1; p = 0.0056) for the unfavorable group. Remaining on AS had no adverse effects on
quality of life, including anxiety and depression. A subsequent prospective observational
study of 143 patients further supported the role for AS in mRCC. In the MaRCC trial,
143 patients were started on AS and were followed for a median of 33.0 months. A total
of 70 patients remained on AS at data cut off and the median overall survival (OS) was
not reached [7]. Altogether, there is ample data to support the role of AS in a subset of
patients with indolent tumor biology and favorable risk disease. Thus, making sure a
patient actually needs any treatment at all for their advanced RCC is the first question to
always address.
3.2. Cytoreductive Nephrectomy Followed by Active Surveillance
The role for cytoreductive nephrectomy (CN) remains heavily debated, and there have
been recent changes to standard practices with decreasing support for upfront nephrectomy.
The data that supported CN stemmed from the early IO era when studies demonstrated
both a progression-free survival (PFS) and OS benefit in those who underwent CN prior to
initiating systemic therapy with IFN-α [8,18]. This practice then came into question as we
developed a more nuanced understanding of the heterogeneity in RCC tumor biology and
in the era of more modern therapies (TKI/ICB). The more contemporary CARMENA and
SURTIME trials were performed in the era of targeted therapies and also account for the
IMDC risk criteria. The CARMENA trial was a non-inferiority randomized control study
investigating CN followed by sunitinib or upfront sunitinib in 450 IMDC intermediate- or

Cancers 2022, 14, 4607

6 of 24

poor-risk patients. The median OS was 18.4 months with sunitinib alone and 13.9 months
for CN followed by sunitinib, indicating non-inferiority (hazard ratio (HR) 0.89; 95% CI,
0.71–1.10) [9]. The SURTIME trial randomized patients to CN followed by sunitinib or
deferred CN after three cycles of sunitinib. The study did not accrue as planned, and
was closed prematurely. However, at 28-week PFS analysis, there was no appreciable
difference in survival between the two groups. Interestingly, there was an OS advantage in
the deferred CN group in the intention-to-treat (ITT) analysis (32.4 m vs. 15.0 m; HR 0.57;
95% CI, 0.34–0.95; p = 0.03) [19]. Together, these trials suggest that upfront CN should be
considered only in carefully selected patients, and that starting with systemic therapy may
confer overall benefit for the mRCC population at large.
We can extrapolate that upfront CN may benefit select patients with few IMDC risk
factors, asymptomatic disease, and minimal metastatic tumor burden [20]. This, however,
is the same patient profile that can benefit from AS, and there is no prospective data to
guide decision making between surgery or AS. In both large AS studies, a subset of patients
had undergone CN prior to AS (or underwent CN during the AS interval). Unfortunately,
the studies do not provide survival analyses in relation to these patient subsets. As such,
we recommend a multidisciplinary discussion taking patient wishes and goals into account
as both AS and upfront CN are viable treatment strategies.
There is growing interest in identifying the ideal patient population for deferred CN
and ongoing studies aim to further refine our understanding of CN. A number of largedataset analyses demonstrated a longer median OS in carefully selected patients with TKI
treatment and deferred CN [21,22]. A recent real-world analysis evaluated the oncologic
role of CN in the modern era of IO, and identified benefit with CN in select patients as
well [23]. Thankfully, we have two prospective phase III randomized control trials underway examining deferred CN in the modern era of IO. Neither study design includes an
upfront CN cohort, which speaks to the diminishing role of this practice. The NORDICSUN
(NCT03977571) study is examining outcomes in select patients (≤3 IMDC risk features)
treated with ipilimumab/nivolumab and deferred CN. The PROBE (NCT04510597) study
allows for multiple front-line systemic therapy options, and if no disease progression, then
patients may proceed with a deferred CN. Both studies are highly anticipated and will
likely shed light on potential survival benefit to systemic therapy alone.
3.3. Upfront Metastasis-Directed Therapy
Metastasis-directed therapy (MDT) should always be a consideration in the event of
brain metastases, extreme pain and cord-compression (or impending cord compromise).
Although TKI therapy can induce rapid disease control and is an attractive option, one
must consider the risk of delayed perioperative intervention due to wound healing or
radionecrosis and compound toxicity. In absence of these extreme circumstances, MDT
with radiotherapy or surgery can be considered depending on degree of tumor burden and
patient comorbidities.
Although RCC has been traditionally considered resistant to radiotherapy, emerging
data is changing this opinion. Conventionally fractioned radiotherapy was previously
examined in RCC with seemingly little antitumor activity [24]. (SBRT) provides a higher
dose of radiation while sparing adjacent healthy tissue from toxicity. This higher dose of
radiation is believed to overcome the theoretical radioresistance mechanisms of RCC [25].
A meta-analysis of 28 studies accounting for 1602 mutually exclusive patients evaluated the
safety and efficacy of SBRT for RCC oligometastases. Although with significant limitations
and not directly applicable to the treatment-naïve population, the study concluded that
stereotactic radiotherapy was safe and efficacious with a local control rate of 90% and
negligible toxicity at 12 months [26]. In a prospective phase II study, definitive SBRT was
assessed as a means to defer systemic therapy in patients with oligometastatic mRCC. The
study enrolled 30 patients who underwent at least one round of radiotherapy. At a median
follow-up of 17.5 months, the PFS was 22.7 months (95% CI, 10.4–NR), and the 12-month
PFS was 64% (95% CI, 48–85) [10]. The role of SBRT as an initial therapeutic modality is

Cancers 2022, 14, 4607

7 of 24

growing, and further studies are likely to further define the role of SBRT in the mRCC
treatment paradigm.
Surgical resection or oligometastasectomy provides an alternative approach to newly
diagnosed mRCC in select patients. There is no high-level prospective data comparing
oligometastasectomy to AS or SBRT. However, opportunity for resection may be encountered in clinical practice, and a multidisciplinary review of these cases is warranted. In an
observational study of complete metastasectomy at first recurrence after partial or radical
nephrectomy, the two-year cancer-specific survival was significantly higher in patients with
surgery to those without (84% vs. 54%; p < 0.001) [11]. Similar results were found in studies
that included resection of metastases to the lung, bone, brain, liver, and pancreas [27,28].
Possibly the most compelling data supporting metastasectomy comes indirectly from the
literature exploring adjuvant therapy. The KEYNOTE-564 trial investigated adjuvant pembrolizumab in patients with locoregional RCC with high risk of recurrence. The study
included a subset of patients who had resection of metastatic lesions conferring a no evidence of disease state (M1 NED) [29]. Treatment with adjuvant pembrolizumab in this
population had a profound impact on DFS (HR 0.28, 95% CI 0.12–0.66). Although the
role of adjuvant IO remains unclear with inconsistent results among large prospective
trials [30,31], metastasectomy conferring M1 NED may serve an opportunity for prolonged
survival in select patients planned for adjuvant therapy.
4. Front-Line Systemic Therapy Options
4.1. IO/IO Combination Therapy
The CheckMate 214 study led to approval of ipilimumab/nivolumab combination
therapy for IMDC intermediate- or poor-risk patients. CheckMate 214 was a phase III
randomized control trial investigating ipilimumab/nivolumab or sunitinib in treatmentnaïve patients. Coprimary end points were ORR, PFS, and OS among intermediate- and
poor-risk patients. Exploratory end points included outcomes according to the tumor
PD-L1 expression (≥1% vs. <1%). The study enrolled 1096 patients in the ITT population.
The pre-defined statistical analyses were focused on IMDC intermediate- and poor-risk
patients, although the study included 249 favorable risk patients as well. Median follow-up
time was 25.2 months at time of initial analysis, and ORR was 42% (95% CI, 37.0–47.0)
with ipilimumab/nivolumab versus 27% (95% CI, 22.0–31.0) with sunitinib (p < 0.001).
There was no median PFS benefit to the IO/IO combination therapy as the hazard ratio for
disease progression or death did not meet prespecified threshold for statistical significance
(HR 0.82; 99.1% CI, 0.64–1.05; p = 0.03). The median OS was not reached (NR) with
ipilimumab/nivolumab versus 26.0 months with sunitinib (HR for death, 0.63; p < 0.001).
In the favorable risk population, the OS, ORR, and PFS all favored sunitinib over ICB
combination therapy. Grade 3/4 treatment-related adverse events (TRAE) occurred in
46% of ipilimumab/nivolumab patients and 63% of sunitinib-treated patients. Highdose glucocorticoid for immune-related adverse events (irAE) were needed in 35% of
ipilimumab/nivolumab patients with a TRAE [32]. Based on this landmark study, the
FDA approved ipilimumab/nivolumab for first-line treatment of IMDC intermediate- and
poor-risk patients in April 2018.
The CheckMate-214 was the first combination therapy in the modern era to report
an OS benefit. We now have extended follow up survival data from the study reported
(Table 2). At 5-year follow-up, dual-ICB continues to demonstrate an improved median OS
over sunitinib in the ITT (HR 0.72; 95% CI, 0.62–0.85) and IMDC intermediate-and poor-risk
(HR 0.68; 95% CI, 0.58–0.81) populations. PFS probabilities also favored ipilimumab over
sunitinib in intermediate-and poor-risk patients (HR 0.73; 95%, CI 0.61–0.87). However, in
favorable risk patients, OS and PFS both favored sunitinib (OS: HR 0.94; 95% CI 0.65–1.37;
PFS: HR 1.60; 95% CI 1.1–2.3) [33].
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Table 2. Front-line immuno-oncology (IO)-based combination therapies in metastatic clear cell RCC with extended follow up-data.
IMDC Risk Group

Intention-to-Treat Population

Favorable
Median TTR
(Months)

mOS
[HR (95%
CI)]

mPFS
[HR (95%
CI)]

ORR
(%)

mOS [HR
(95% CI)]

mPFS
[HR (95%
CI)]

ORR
(%)

10.7
vs.
2.6 *

2.8 vs. 4.0 *

74.0
vs.
68.0
[0.94
(0.65–1.37)]

12.4 vs. 28.9
[1.60
(1.1–2.3)]

30.1
vs.
52.6

47.0 vs.
27.0
[0.68
(0.58–0.81)]

12.0
vs.
8.0 [0.73
(0.61–0.87)]

42.1
vs.
27.2

10.0 vs. 3.5

2.8 vs. 3.0

NR [1.17
(0.76–1.80)]

20.7 vs. 17.8
[0.76
(0.56–1.03)]

68.8
vs.
50.4

Not reported
[0.64
(0.52–0.80)]

13.8 vs. 8.2
[0.67
(0.55–0.81)]

56.5 vs. 34.9

Int
NR vs. NR
[0.74
(0.50–1.08)]

Int
17.5 vs. 8.5
[0.58
(0.45–0.76)]

Int
55.9 vs. 28.7

Poor
NR vs. 11.2
[0.45
(0.27–0.76)]

Poor
9.9 vs. 4.2
[0.36
(0.23–0.56)]

Poor
37.7 vs. 10.3

NR vs. NR
[0.58
(0.42–0.80)]

22.1 vs. 5.9
[0.36
(0.28–0.47)]

72.4 vs. 28.8

mOS
[HR (95%
CI)]

mPFS
[HR (95%
CI)]

ORR
(%)

Median
DOR
(Months)

CR
(%)

Checkmate
214 #
Ipi/Nivo
vs.
Sunitinib

56.0 vs. 38.0
[0.72
(0.62–0.85)]

12.0 vs. 12.0
[0.86
(0.73–1.01)]

39.12
vs.
32.3

NR
vs.
25.0

KEYNOTE
426 ##
Pembro/Axi
vs.
Sunitinib

45.7 vs. 40.1
[0.73
(0.60–0.88)]

15.7 vs. 11.1
[0.68
(0.58–0.80)]

60.4 vs. 39.6

23.6 vs. 15.3

CheckMate
9ER
Nivo/Cabo
vs.
Sunitinib

NR vs. 29.5
[0.66
(0.50–0.87)]

17.0 vs. 8.3
[0.52
(0.43–0.64)]

54.8 vs. 28.4

CLEAR
Pembro/
Lenvatinib
vs.
Sunitinib

NR vs. NR
[0.66
(0.49–0.88)]

23.9 vs. 9.2
[0.39
(0.32–0.49)]

71.0
vs. 36.1

20.2 vs. 11.5

25.8 vs. 14.6

Intermediate/Poor

9.3 vs. 4.3

16.1 vs. 4.2

2.8 vs. 4.5

1.94 vs. 1.94

NR vs. NR
[0.94
(0.46–1.92)]

24.7 vs. 12.8
[0.58
(0.36–0.93)]

66.2
vs.
44.4

NR vs. NR
[1.15
(0.55–2.40)]

28.1 vs. 12.9
[0.41
(0.28–0.62)]

68.2 vs. 50.8

DOR, duration of response; TTR, Time to response; Ipi, Ipilimumab; Nivo, Nivolumab; Pembro, Pembrolizumab; Axi, Axitinib; Cabo, Cabozantinib; ORR, objective response rate; mPFS,
median progression-free survival; HR, hazard ratio; NR, not reached; mOS, median overall survival. # Extended 5-year follow-up data, * Extended 4-year follow-up date, ## Extended
3.5-year follow-up date.
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4.2. IO/TKI Combination Therapy
The early individual success of nivolumab monotherapy and of older-generation
targeted therapies naturally led to the investigation of IO/TKI combination strategies.
In fact, early data suggest that anti-angiogenesis therapy promotes antitumor immune
responses within the tumor microenvironment, and combination approaches mutually
enhance the effects of anti-angiogenesis and IO therapy [34]. The first landmark IO/TKI
combination trial was the KEYNOTE-426 study, which employed axitinib in combination
with pembrolizumab or sunitinib in 861 treatment-naïve patients. This combination therapy
was approved by the FDA in April 2019, and has the longest follow-up data among all
IO/TKI regimens. The primary end points were OS and PFS in the ITT population. The
key secondary end point was the ORR. At time of initial reporting after a median follow-up
of 12.8 months, survival analysis favored axitinib/pembrolizumab over sunitinib (HR 0.53;
95% CI, 0.38–0.74; p < 0.0001). Median PFS for axitinib/pembrolizumab and sunitinibtreated patients were 15.1 months and 11.1 months, respectively (HR 0.69; 95% CI, 0.57–0.84;
p < 0.001). ORR was 59.3% (95% CI, 54.5–63.9) in the axitinib/pembrolizumab group and
35.7% (95% CI, 31.1–40.4) in the sunitinib group (p < 0.001). Importantly, the superior
outcomes from with IO/TKI combination therapy were observed across all IMDC risk
groups [35]. With extended follow up, and a median follow-up of 30.6 months, a continued
clinical benefit was observed with combination therapy in OS (HR 0.68; 95% CI 0.55–0.85,
p = 0.0003) and PFS (15.4 months vs. 11.1 months, p < 0.0001) [36].
Following a similar trial design, the CheckMate 9ER study randomized 651 treatmentnaïve patients with clear cell mRCC to cabozantinib/nivolumab or sunitinib. The primary
endpoint was PFS. Secondary endpoints were OS and ORR. The median PFS was 16.6 months
(95% CI, 12.5–24.9) for cabozantinib/nivolumab and 8.3 months (95% CI, 7.0–9.7) for sunitinib.
The OS (HR 0.60; 98.89% CI, 0.40–0.89; p = 0.001) and ORR (55.7% vs. 27.1%; p < 0.001) also
favored the combination regimen. These benefits were noted across IMDC risk groups [37]
(Table 2).
Most recently, a third IO/TKI combination regimen gained FDA approval for use
in mRCC. The CLEAR study demonstrated the efficacy of lenvatinib/pembrolizumab
combination therapy. The phase III randomized trial assigned 1069 patients in a 1:1:1 ratio
to lenvatinib/pembrolizumab, lenvatinib/everolimus or sunitinib. The study’s primary
endpoint was PFS, and secondary endpoint was OS. Lenvatinib/pembrolizumab demonstrated a significantly longer PFS than sunitinib in the ITT population (median PFS 23.9 vs.
9.2 months; HR, 0.39; 95% CI, 0.32–0.49; p < 0.001). Median OS was not reached in either
treatment arm, but the OS was longer with lenvatinib/pembrolizumab than with sunitinib
(HR 0.66; 95% CI, 0.49–0.88; p = 0.005) (Table 2). Importantly, the CLEAR data reported an
ORR of 71% and a CR rate of 16% in lenvatinib/pembrolizumab treatment patients [38].
Three alternative combination therapies have been studied and may be considered for
use, although they are not guideline-recommended as front-line choices. The JAVELIN Renal
101 trial was a phase III study comparing avelumab/axitinib with sunitinib. The study
focused on PD-L1-positive tumors, with coprimary endpoints of PFS and OS in this biomarker
subset [39]. Extended follow-up results demonstrated benefit to avelumab/axitinib over
sunitinib across IMDC risk strata for ORR, but only benefit in for PFS and OS among IMDC
intermediate/poor-and poor-risk disease [40]. An alternative IO/TKI combination therapy
with emerging efficacy data is axitinib/nivolumab. A phase I/II study investigating this
combination in treatment-naïve patients and patients previously treated with TKIs alone or
IO/IO combination. In the treatment-naïve group, ORR was 69.0% and a disease control rate
(DCR) of 97.6%. Median PFS was 16.4 months (95% CI, 10.6–21.9) and median OS was not
reached [41].
5. Factors to Consider with Front-Line Therapy Options
5.1. Opportunity for Multidisciplinary Approach
Prior to deciding between systemic therapy options, we recommend evaluating patient
candidacy for active surveillance or metastasis-directed therapy. Metastatic RCC remains
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largely incurable, and studies have demonstrated the safety and added value (in QoL and
survival) of AS in select patients. We strongly recommend considering AS for favorable
risk patients with limited tumor burden and indolent growth. The CARMENA trial
showed possible benefit for CN in a patient subset with similar characteristics. To this
end, some patients undergoing AS can also be considered for CN (either upfront or during
the AS period), but we generally caution against this practice at least until more data
emerges from ongoing trials. However, we do consider CN in symptomatic patients
who may have uncontrolled hematuria or localized pain from the primary tumor. In
the setting of oligometastatic disease with overall indolent tumor biology aside from 1 to
2 growing lesions, metastasis-directed therapy with metastasectomy or SBRT are reasonable
approaches with emerging supporting data. Taken together, an individualized approach to
each patient is recommended, and if there is opportunity to avoid or defer systemic therapy,
a multidisciplinary review of the case is appropriate.
5.2. Characterization of the Tumor Biology
Clinical decision making should account for tumor biology. Sarcomatoid differentiation appears in approximately 8% of clear cell tumors but is present in nearly 20% of
metastatic RCC [42,43]. The sarcomatoid disease is typically more aggressive and historically responds poorly to anti-angiogenesis therapy. In the CheckMate 214 trial, 139 patients
with intermediate- and poor-risk disease had sarcomatoid histology. In this subset of
patients, median OS was not reached with ipilimumab/nivolumab and was 14.2 months
with sunitinib (HR 0.45; 95% CI, 0.3–0.7; p = 0.0004). Median PFS also heavily favored ipilimumab/nivolumab (median 26.5 vs. 5.1 months; HR, 0.54 (95% CI, 0.33–0.86; p = 0.0093)).
The most pronounced benefit was observed in ORR, which was 60.8% (complete response
18.9%) for ipilimumab/nivolumab and 23.1% (complete response 3.1%) with sunitinib. [44].
Subgroup analyses from the KEYNOTE-426, CheckMate9ER, and CLEAR studies have
also shown substantial benefits from IO/TKI combination therapy over TKI monotherapy
(Table 3). Meta-analysis of patients with sarcomatoid histology from multiple ICI-based
randomized control trials also demonstrates this benefit in OS, PFS, ORR, and complete
response (CR) rate [45]. In the absence of a contraindication to IO, we believe all patients
with clear cell mRCC with sarcomatoid differentiation should be treated with a front-line
ICB-based systemic therapy regimen. Ipilimumab/nivolumab remains the regimen with
the longest follow-up and with the highest ORR and CR rate within this population.
PD-L1 expression as a predictive biomarker has been extensively studied in mRCC.
In the CheckMate 214 study, ipilimumab/nivolumab showed a PFS benefit over sunitinib
in PD-L1-positive tumors, but not in PD-L1-negative tumors (PD-L1 < 1%). However, in
the IMDC intermediate-and poor-risk patients, PD-L1 expression did not correlate with
response. IO/TKI therapy demonstrated benefit regardless of PD-L1in the KEYNOTE426, CheckMate 9ER, and CLEAR studies. The studies were not consistent in regards to
definition for PD-L1 positivity and employed different commercial assays for PD-L1 in
each respective study. At this time, PD-L1 as not a clinically validated predictive biomarker
in mRCC and we do not incorporate its expression in our routine decision making.
Considering whether there are genomic contributions at play is important since identifying a hereditary RCC syndrome can occasionally affect clinical management and clinical
trial participation. The National Comprehensive Cancer Network guidelines recommend
genetic risk evaluation in all RCC patients who meet prespecified criteria, namely that they
(1) have a close blood relative with a known pathogenic variant in a cancer susceptibility
gene, (2) have been diagnosed at age <46 years, (3) have bilateral or multifocal tumors,
(4) have ≥1 first- or second-degree relative with RCC, and (4) have tumors that are characterized by certain specified histologic characteristics [46]. Identification of a genetic syndrome
or germline gene may also warrant expert pathology review of tumor tissue, as rare histologies can be mistakenly identified as clear cell histology when they actually represent a
rarely encountered histologic subtype necessitating alternative treatment strategy.
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Table 3. Summary of efficacy of ICB-based systemic therapy in mRCC with sarcomatoid features.
Trial

CheckMate 214

KEYNOTE-426

CheckMate 9ER

CLEAR

Sample Size

ORR (%)

CR (%)

PFS
(Months)

Ipi + Nivo
(n = 74)

61.0

19.0

26.5

Sunitinib
(n = 65)

23.0

3.0

5.1

Pembro + Axi
(n = 46)

58.8

13.0

NR

Sunitinib
(n = 50)

31.5

2.0

8.4

Nivo + Cabo
(n = 34)

54.8

9.3

10.3

Sunitinib
(n = 41)

28.4

4.3

4.2

Pembro + Lenvatinib
(n = 28)

60.7

NA

11.1

Sunitinib
(n = 21)

23.8

NA

5.5

HR PFS
(95% CI)
0.54
(0.3–0.9)

OS
(Months)
NR
14.2

HR OS
(95% CI)
0.45
(0.3–0.7)

NR
0.52
(0.29–1.00)

0.42
(0.23–0.74)

NR
NR
19.7

0.58
(0.21–1.59)

0.36
(0.17–0.79)

NR
0.39
(0.18–0.84)

NR

0.91
(0.32–2.58)

Ipi, ipilimumab; Nivo, Nivolumab; Sun, Sunitinib; Pembro, Pembrolizumab; ORR, objective response rate; CR,
complete response; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; NR, not reached; NA,
not available.

5.3. Patient Characteristics and Toxicity
Anticipating a patient’s ability to tolerate therapy is essential to treatment planning.
Avoiding dose reductions and treatment interruptions should be a determinant in choice
of therapy. Front-line combination therapy remains standard of care at this time, and we
believe that all patients should be considered for an ICB-based doublet therapy (IO/IO or
IO/TKI) in the absence of contraindication or significant co-morbidity. History of autoimmune disease or solid-organ transplant remain the strongest considerations in avoiding IO.
In these cases, TKI monotherapy can still provide effective disease control with durable
outcomes in some. There is robust data supporting the use of cabozantinib monotherapy,
especially in IMDC intermediate-and poor-risk patients where it has superiority over other
single-agent anti-angiogenesis therapy [37]. Sunitinib remains a reasonable TKI to consider
in some IMDC favorable risk patients who are not candidates for IO, especially considering
there is no proven OS benefit here over dual-ICB therapy to date [37].
TKI therapy is associated with significant toxicity. The landmark IO/TKI studies
had higher incidence of grade ≥ 3 toxicities than in CheckMate 214, most of which are
attributable to the TKI. These toxicities are predictable, and typically resolve with dose
reduction or treatment breaks. However, poor wound healing, vascular disease, severe
coronary artery disease, recent CVA, or uncontrolled hypertension all represent co-morbid
conditions, which may be barriers to safe TKI use altogether. Dual or sometimes single-ICB
therapy represents an ideal treatment consideration in this patient subset.
The nature of the toxicities differ between IO and TKI classes, and these toxicities
should be taken into consideration during patient-centered decision making. The majority
of toxicity incurred from IO/TKI combination therapy is attributable to the TKI. Although
TKI-associated toxicity is common, it is predictable and can be mitigated with preventive
measures, dose reductions, or treatment breaks. Some patients may choose to avoid the
reality of day-to-day TKI-associated toxicity, which affects QoL, and may instead choose
dual-ICB therapy. Ipilimumab/nivolumab use has QoL metrics supporting its use over TKI
therapy with improved patient-reported outcomes [47]. Conversely, patients with severe
end-organ disease (e.g., COPD, CKD) may want to avoid the risk of grade ≥ 3 irAE, which
may be life threatening given poor organ reserve. These patients may choose for more
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day-to-day toxicity from IO/TKI and avoid the 47% risk of grade ≥ 3 irAE from IO/IO,
which may cause long lasting morbidity or death.
Financial toxicity remains a factor to consider as certain regimens may burden patients with out-of-pocket costs. Costs associated with mRCC treatments have sharply
increased over recent years [48]. Identifying the most cost-effective combination therapy
is an area of ongoing study. A recent analysis explored the lifetime cost-effectiveness
between ipilimumab/nivolumab, axitinib/pembrolizumab and sunitinib and concluded
ipilimumab/nivolumab was the most cost-effective treatment option (accounting for costs
of drug treatment, adverse events, and utilities associated with different health states) [49].
Utilizing the data from CheckMate 214 in conjunction with the U.S. 2017 Healthcare Cost
and Utilization Project, investigators performed a cost analysis using temporal trends and
costs related to grade ≥ 3 TRAE. Treatment with ipilimumab/nivolumab was associated
with lower grade ≥ 3 TRAE costs than sunitinib [50]. Ongoing studies will help us better
explore the financial toxicity associated with newer therapies, but cost considerations are
complex and vary tremendously on a patient-to-patient basis based on insurance coverage
or lack thereof. Therefore, we recommend an individualized patient discussion surrounding out-of-pocket expense and overall financial toxicity (including time off work for clinic
appointments and infusions, costs associated with potential TRAE, childcare/elder care
expenses, and travel costs). These practices are now supported by the ASCO guidelines for
management of mRCC [51].
5.4. Tumor Burden
In patients with a bulky tumor burden, symptomatic disease, or evidence of endorgan dysfunction, rapid treatment response is necessary. In these settings, ORR and
risk of primary progression are clinical endpoints we prioritize. Of all the approved
doublet therapies, lenvatinib/pembrolizumab provides the highest ORR (ITT ORR: ipilimumab/nivolumab 39.1%, axitinib/pembrolizumab 60.4%, nivolumab/cabozantinib
54.8%, and lenvatinib/pembrolizumab 71.0%), although the study enrolled the highest
proportion of IMDC favorable risk patients. Lenvatinib/pembrolizumab also demonstrated
the shortest median time to response (1.94 months), although the CLEAR study protocoldefined timepoint for first response evaluation was at 8 weeks, as opposed to 12 weeks in
the other landmark trials of interest. Numerically, lenvatinib/pembrolizumab provides the
greatest chance of rapid treatment response, or at least disease control, among front-line
options. However, lenvatinib/pembrolizumab-treated patients also have the highest rate
of grade ≥ 3 TRAE and drug discontinuation rates among the combination therapies and
this treatment regimen has no clear OS advantage over other combination therapies.
Location of metastases with respect to overall tumor burden can also guide therapy. Presence of bone metastases are common in mRCC and are associated with poor
prognosis [52]. In pre-clinical prostate xenograft studies, cabozantinib had direct effect
on osteoblast activity while inhibiting osteoclasts. In clinical study, cabozantinib led to
increased bone scan responses and decreased turnover in prostate cancer patients. This provided the biologic rationale for exploration of skeletal-related events (SREs) in the mRCC
setting. Subgroup analysis from the phase III METEOR trial investigating cabozantinib and
everolimus in previously treated mRCC suggested cabozantinib may have unique activity
against bony disease as survival and response rates were higher and bone turnover was
lower in patients with baseline bone metastases [53]. Post hoc analysis from the CheckMate 9ER similarly revealed that combination treatment with cabozantinib/nivolumab
had more pronounced efficacy in patients with bone metastases compared to those without [54]. The phase II A031801 (RadiCal) trial through Alliance will employ cabozantinib
in combination with Radium-223 or cabozantinib alone in a patients with symptomatic
bone metastases. Correlative analyses from this study may better define cabozantinib
tropism for bone metastases (NCT04071223). Brain metastases are also challenging to
treat and associated with morbidity and early mortality. TKI’s are not conventionally
believed to have central nervous system (CNS) activity, however cabozantinib has recent
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pre-clinical data suggesting blood-brain barrier penetration [55]. A proposed mechanism
here is direct targeting of cMET, which is enriched in mRCC brain metastases. In a large and
well-designed retrospective analysis of mRCC patients with brain metastases, cabozantinib
demonstrated CNS activity with an intracranial response rate of 55% (95% CI, 36–73%) without concurrent brain-directed local therapy [56]. Taken together, cabozantinib/nivolumab
represents an ideal candidate for treating patients with baseline bone or brain metastases.
Alternatively, ipilimumab/nivolumab’s activity in the CNS was directly assessed in the
CheckMate 920 study, which was the first prospective trial of first-line dual-ICB therapy inclusive of patients with brain metastases. The study demonstrated an ORR of 32% (95% CI,
15–54%), although no complete responses. Based on this study, ipilimumab/nivolumab is
an alternative regimen to consider for patients with CNS disease.
Axitinib/pembrolizumab represents the IO/TKI option with the most mature efficacy
and safety data and is an attractive front-line option. Axitinib/pembrolizumab provides
an opportunity for rapid disease control and prolonged survival, with fewer grade ≥ 3
TRAE than other IO/TKI regimens, and fewer treatment discontinuations than lenvatinib/pembrolizumab [35,57]. Further, axitinib is a potent TKI with a short half-life. The
short half-life allows for quick washout pre-procedurally when surgical intervention in
warranted. Differentiating TKI and IO toxicity is often challenging, but axitinib-related
adverse effects typically resolve or improve more rapidly than other TKIs owing to its short
half-life. To this end, it is often easier differentiating an irAE from TKI toxicity with axitinib.
Axitinib pharmacokinetics (twice daily dosing schedule) along with the 1 mg formulary
tablets allow for ease in titration to optimize efficacy, while minimizing adverse effects [58].
Employing axitinib/pembrolizumab in the front-line setting may be advantageous
for survival when considering treatment sequencing. Cabozantinib has proven efficacy
after prior anti-angiogenesis, and its multitarget activity bypasses mechanisms of resistance
to older-generation TKIs such as axitinib and sunitinib. As such, cabozantinib is an ideal
second-line agent in patients treated with non-cabozantinib-based front-line combination
therapies. Indeed, cabozantinib monotherapy was the most commonly employed secondline therapy after axitinib/pembrolizumab per KEYNOTE-426 [35]. Similarly, lenvatinibnaïve patients may be considered for treatment with lenvatinib/everolimus combination
therapy in the second- or third-line settings. Employing axitinib/pembrolizumab upfront
leaves these efficacious salvage options available for future use, potentially positively
affecting overall survival. However, optimal sequencing is not well defined and requires
further investigation.
Ipilimumab/nivolumab use is supported by long-term follow-up data, and has the
ongoing appeal of a durable response. We consider ipilimumab/nivolumab in IMDC
intermediate-and poor-risk patients who are not in need of a rapid response and can
tolerate risk of primary progression. The treatment schedule entails four doses of dual-ICB
therapy, and is followed by a very manageable and well-tolerated maintenance nivolumab
phase free of daily oral medications and their associated chronic toxicities. In fact, patients
treated with ipilimumab/nivolumab had a significantly improved health-related quality
of life (HRQoL) over those treated with sunitinib in prospective study [32]. Although
durable responses are not exclusive to patients treated with ipilimumab/nivolumab, the
long-term follow-up data are exceptional here. The PFS curves in the ITT and IMDC
intermediate-and poor-risk populations plateaued at 24-months and have not fluctuated
significantly. Moreover, the HR for OS has also remained constant throughout the ongoing
extended follow up from CheckMate 214. This is in contrast to follow-up data from all
three IO/TKI regimens, which reveal a slowly rising HR suggesting slow but steady loss of
treatment effect. Further maturation of the data will certainly clarify long-term survival
efficacy, but as of now, ipilimumab/nivolumab provides the most durability in response
among approved regimens [5,32,35–38,57,59].
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5.5. Employing Real-World Evidence in Lieu of Head-to-Head Data
Cross-trial comparisons are inherently fraught with flawed conclusions, and there is
generalized caution against this practice [60,61]. However, in the absence of head-to-head
trials among front-line mRCC treatment options, we often rely on data extrapolation. Randomized control trials remain the gold standard for evaluating interventions. However, in
attempt to minimize confounders and bias, studies employ strict inclusion and exclusion
criteria negatively impacting external validity [62]. Real-world analyses from large datasets
can provide evidence that is generalizable and can inform clinical decision making (as well
as future trial design and healthcare policy) [63]. A large, retrospective observational study
utilizing a longitudinal database with 1506 patients treated with ipilimumab/nivolumab
or axitinib/pembrolizumab in both the community and academic settings examined patient outcomes (median follow-up time 20.0 months, range 0.4–47.6 months). The median OS for the full population was 28.9 months for axitinib/pembrolizumab and was
24.3 months for ipilimumab/nivolumab (p = 0.09). Twenty-four-month survival was
53.8% for axitinib/pembrolizumab-treated patients and 50.2% for ipilimumab/nivolumabtreated patients. Real-world PFS was 10.6 months for axitinib/pembrolizumab-treated
patients and 6.9 months for ipilimumab/nivolumab-treated patients. Interestingly, axitinib/pembrolizumab therapy conferred benefit in PFS and OS in the IMDC favorable
risk population [64]. In a separate real-world analysis employing the IMDC database,
clinical outcomes were assessed in 723 intermediate-and poor-risk patients treated with
ipilimumab/nivolumab or IO/TKI combination therapies. There was no discernable OS
difference between treatment groups [65]. The outcomes from these studies are generally
concordant with historical trial data, which is noteworthy and reassuring. The blunted
efficacy and survival observed in these real-world patients is expected and speaks to the
efficacy-effectiveness gap, which typically exists for contemporary cancer therapies [66].
This real-world survival data can certainly assist with bedside patient conversations and
prognostication when it comes to choosing therapy.
5.6. Can We Consider Ipilimumab/Nivolumab for IMDC Favorable Risk Disease?
Treatment with dual-ICB has distinct benefits to consider in the favorable risk population. Treatment-free survival (TFS) is a clinical endpoint developed in the modern IO
era, which characterizes the time free of systemic anticancer therapy, while accounting for
ongoing systemic toxicity [67]. In the 42-month follow-up of CheckMate-214, the mean TFS
was considerably longer with ipilimumab/nivolumab than sunitinib for intermediate-and
poor-risk patients (6.9 vs. 3.1 months). The TFS difference was even more pronounced in
favorable risk patients (11.0 vs. 3.7 months). This includes TFS free of toxicity as well [68].
In the IMDC favorable risk cohort from CheckMate 214, considerably more patients
achieved a CR with ipilimumab/nivolumab than with sunitinib (12.0% vs. 6.5%) [37]. Moreover,
the probability of maintaining a response ≥4 years is higher with ipilimumab/nivolumab in
the favorable risk category, 60% (95% CI, 0.41–0.75) vs. 38% (95% CI, 0.22–0.54) with sunitinib.
Conditional 5-year survival is now also favoring ipilimumab/nivolumab (63% vs. 55%) [69].
Following current treatment guidelines, however, any patient treated with front-line IO/TKI will
likely never receive anti-CTLA-4 therapy in their treatment course. This is unsettling, considering
the lost opportunity for a durable response for many of these patients. The phase II HCRN
GU16-260 trial investigated the role of salvage ipilimumab as a means of converting suboptimal
responses with alternative front-line treatment. Unfortunately, salvage ipilimumab/nivolumab
showed limited activity with an ORR of only 11% and only one CR [70]. We may see a growing
role for dual-ICB therapy among IMDC favorable risk patients in the future, especially if there
is growing sentiment that patients should receive the most active ICB regimen perceived to be
tolerable upfront [70].
Another IO option that should not be overlooked for IMDC favorable risk patients is
pembrolizumab monotherapy. The KEYNOTE-427 was a multicenter, open-label phase II
study of pembrolizumab monotherapy in clear cell mRCC (cohort A). The study enrolled
41 patients with IMDC favorable risk disease. The ORR among these patients was 31.0%

Cancers 2022, 14, 4607

15 of 24

(95% CI, 17.6–47.1) and the DCR was 61.9% (95% CI, 45.6–76.4). Notably, the adverse
event profile is considerably milder than IO/TKI or IO/IO combination therapy, with a
grade ≥ 3 irAE occurring in only 15.1% of patients [71].
Developing IO-specific predictive biomarkers and prediction models can have transformative impact in the treatment paradigm. Interestingly, recent studies categorized
mRCC patients by molecular subgroups that predicted treatment responsiveness to IO.
There was no correlation between the immunogenic molecular subgroup and IMDC score,
and all subgroups were present in all IMDC risk groups [72]. At this time, we do not
typically consider IMDC favorable risk patients for dual-ICB therapy or pembrolizumab
monotherapy if the patient is a candidate and agreeable to IO/TKI regimens, however
further study is certainly warranted to optimize treatment selection in this space.
5.7. Prior Treatment with IO in the Adjuvant Setting
The KEYNOTE-564 trial demonstrated that patients with high-risk RCC treated with
adjuvant pembrolizumab benefited from prolonged disease-free survival, although the
extent of that benefit is unclear with maturing OS data [29]. As the role of adjuvant
IO is evolving for early-stage RCC, there are unanswered questions as to how to treat
these patients if disease were to recur. ICB-based combination strategies provide patients
the greatest chance of response and greatest depth of response. However, the role of
immunotherapy rechallenge in this setting is yet to be defined. We do not fully understand
the inherent tumor resistance mechanisms for patients who develop recurrence while on
adjuvant therapy (or shortly thereafter) and in those who have a prolonged disease-free
interval prior to recurrence. As such, there is a new need for high-level prospective data in
this arena. In the absence of such data, we will need to extrapolate from completed and
ongoing trials in the post-ICI mRCC setting.
The phase III OMNIVORE trial was a carefully designed response-adapted study in
which patients were treated with single-agent nivolumab followed by response-based ipilimumab as a salvage strategy. There was a remarkably low conversion rate of nivolumab
non-responders, as only 2 of 57 patients treated with salvage IO converted to a partial
response (while no CRs were observed) [73]. An additional relevant study is a phase
Ib/II KEYNOTE-146 trial, which included a cohort assessing lenvatinib/pembrolizumab in
ICB-pretreated patients. The study showed that salvage ICB-based combination therapy is
feasible in this population, although with dampened efficacy compared to the treatmentnaïve cohort [74]. There are ongoing studies (e.g., PDIGREE [NCT03793166], CONTACT-03
[NCT04338269], TiNivo-2 [NCT04987203]) which may provide further insight into optimal treatment approach here. Invariably, we anticipate and welcome carefully designed
prospective studies for patients previously treated with adjuvant-ICB to better determine
optimal treatment sequencing.
6. Ongoing Areas of Study within the Front-Line Treatment Paradigm
6.1. Predictive Biomarkers
There are no clinically validated predictive or prognostic biomarkers to guide treatment selection currently available. This remains an urgent and unmet need, as treatment
responsiveness remains highly variable, and most patients will eventually develop resistance to treatment, let alone the risk of primary progression. Conventional biomarkers
utilized in other immunogenic tumor types, such as PD-L1 and tumor mutational burden, do not show a consistent correlation with treatment outcomes across studies, albeit
the studies were not uniformly designed and have significant limitations, hindering our
interpretation of clinically utilizable data.
Single-gene biomarkers showed initial promise, with special attention to PBRM1,
SMARCA4, and SETD2 among others. PBRM1 loss or mutation is prevalent in clear cell
RCC and is associated with a nonimmunogenic tumor phenotype and possibly increased
responsiveness to anti-angiogenesis therapy [75,76]. However, utility is limited as this
association has yet to be established in large prospective randomized study. Single-gene
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biomarkers have not demonstrated replicable predictive ability in major studies. We now
understand that transitioning from single-gene biomarkers to gene expression signatures
may have greater impact. A correlative study from the IMmotion 151 trial established a
transcriptomic map of enrolled patients. This study enrolled 915 IMDC all-risk patients
to receive either atezolizumab/bevacizumab or sunitinib. The study did not meet its
primary endpoint and failed to demonstrate an overall survival benefit to combination
therapy, but its well-conceptualized exploratory analysis helped define the biology of
mRCC. The analysis revealed seven molecular subtypes representing cluster patterns of
underlying disease biology. Patient tumors characterized by immunogenic/inflammatory
clusters (T-effector/proliferative, proliferative, and small nucleolar RNA transcription
profiles) had improved survival outcomes when treated with ICB. However, patients
with tumors enriched with angiogenesis clusters did not derive benefit from added IO to
anti-angiogenesis [72].
The phase II BIONIKK study was the first trial to prospectively allocate patients to
treatment groups based on a pre-defined 35-gene mRNA signature profile. Treatment
arms included TKI monotherapy, ICB monotherapy, or dual-ICB combination therapy [77].
The study nicely demonstrated the feasibility of biomarker-based personalized treatment
in mRCC and served as a prime example of the potential for biomarkers for ongoing
trial development. Building upon BIONIKK, we are eagerly awaiting the phase II OPTIC
trial, which is not yet recruiting (NCT05361720). OPTIC will employ the aforementioned
biologic clusters and prospectively assign patients to IO/IO or IO/TKI combination therapy,
depending on tumor genomics.
Despite this ongoing progress, we are still in need of further biomarker development
with a focus on deciphering ideal TKI selection among the various IO/TKI regimens.
There are certainly differences between axitinib, lenvatinib, and cabozantinib based on
targets and further investigation into IO/TKI synergism and angiogenesis signatures may
enable clinically impactful biomarker development in this space. Further, investigators
are assessing alternative biomarkers for response to PD-1/PD-L1 therapy, although these
remain grossly inconsistent and not relevant for clinical practice quite yet [78].
6.2. Immunomodulation
The RCC immune milieu is dynamic, and response to ICB is dependent on multiple
factors that are not yet fully understood. The gut microbiome has a direct influence on the
response to anti-PD-1 immunotherapy in cancer patients [79]. Interestingly, studies suggest
an interplay between the microbiome and the RCC tumor microenvironment, with temporal
changes in microbiota through ICB treatment course [80]. Taken together, there is the
biologic rationale for further investigation of gut microbiome modulation to augment the
immunogenicity of mRCC. In an open-label prospective study, patients were randomized
in a 2:1 fashion to receive ipilimumab/nivolumab with or without daily oral CBM588 (a
bifidogenic live bacterial product). Interestingly, the PFS was longer in patients receiving
the oral bacterial product (12.7 months vs. 2.5 months, HR 0.15, 95% CI, 0.05–0.47, p = 0.001).
ORR also favored the CBM588 treatment arm, although this result was not statistically
significant (58% versus 20%, p = 0.06). There was no additional significant toxicity due
to CBM588 [81]. These data warrant larger studies further exploring opportunities for
immunomodulation in conjunction with both standard ICB and novel therapies.
6.3. Future Therapies and Ongoing Clinical Trials
Novel upstream targets within the VHL-HIF-VEGF axis are being investigated. Smallmolecule inhibitors targeting HIF-2α are being developed, with a few under clinical investigation [82]. Belzutifan (MK-6482) is a second-generation HIF-2α inhibitor with remarkable
efficacy in von Hippel–Lindau disease-associated RCC [83]. Naturally, MK-6482 is now
under active investigation in sporadic mRCC. Favorable results from a phase I study in a
heavily pretreated population have further increased enthusiasm toward this agent. Of
55 patients with clear cell mRCC across all IMDC risk groups, the ORR was 25%, and the
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DCR was 80%. Median PFS was 14.5 months (95% CI, 7.3–NR). These remarkable antitumor
responses were in the setting of a manageable toxicity profile [84]. In the front-line setting,
the open-label phase II MK-6482-003 study is actively recruiting patients to undergo treatment with a combination of belzutifan and cabozantinib. The primary endpoint is ORR,
and secondary endpoints include PFS and OS. It will be interesting to see if combination
therapy targeting multiple drivers within the VHL canonical pathway will have synergistic
effects (NCT03634540) (Table 4).
Treatment intensification beyond doublet therapies may provide higher ORRs and
deeper responses than currently approved options. The highly anticipated COSMIC-313
trial is a large randomized control, double-blind phase III study investigating triplet therapy with nivolumab/ipilimumab with or without cabozantinib in previously untreated
IMDC intermediate-and poor-risk patients. Topline results reported that triplet therapy
significantly reduced the risk of disease progression (HR for PFS, 0.73; 95% CI, 0.57–0.94;
p = 0.01). Overall survival and full safety profiles are pending maturity, but it is possible
that this trial will gain regulatory approval in the near future if mature results remain
positive. Triplet therapy is also being investigated with belzutifan. The phase III MK6848-012 trial is an elegantly designed randomized trial that plans to recruit 1,431 patients
to receive lenvatinib/pembrolizumab, lenvatinib/pembrolizumab + belzutifan, or lenvatinib/pembrolizumab + quavonlimab, which is a novel CTLA-4 antibody (NCT04586231).
Conversely, there are also prospective trials investigating treatment deintensification.
The phase III CA209-8Y8 trial is investigating outcomes in previously untreated IMDC
intermediate- or poor-risk patients when treated with ipilimumab/nivolumab combination
therapy or nivolumab monotherapy (NCT03873402). The TIDE-A study is an elegantly designed phase II in which IO/TKI-treated patients discontinue their TKI and continue with
IO maintenance (NCT04698213). This study follows the rationale that TKIs are particularly
important for initial disease control, whereas IO has more long-term antitumor activity.
Both these trials certainly have the potential to change clinical practice.
Novel IO-based strategies are under investigation, either to augment ICB or to potentiate alternative immune mechanisms. Bempegaldesleukin is a PEGylated IL-2 that recently
gained FDA breakthrough designation in metastatic melanoma. It has been employed in
the mRCC space as well, with early-phase I/II data demonstrating safety and efficacy in
conjunction with nivolumab as first-line therapy in mRCC [85]. The subsequent larger
phase III PIVOT-09 trial failed to meet the prespecified boundary for significance for ORR
or OS, and the trial was discontinued. Final results are yet to be reported (NCT03729245).
As we further elucidate the molecular underpinnings of mRCC, we expect to see
novel therapeutic targets emerge in prospective clinical studies. Epigenetic regulation is a
fitting approach as histone deacetylases (HDACs) are overexpressed in RCC, with lower
protein acetylation in non-cancerous renal tissue [86,87]. HDAC inhibitors abexinostat and
vorinostat have both demonstrated antitumor activity with acceptable safety profiles when
paired with anti-angiogenesis therapy in early-phase trials [88,89]. A randomized, phase
III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in
previously untreated patients is now underway (NCT03592472).
Investigators continue to explore new approaches to RCC tumorigenesis in pre-clinical
and early-phase studies. These include and are not limited to: metabolic reprogramming
with a focus on RCC cancer cell metabolites, repurposing drugs already employed in
other tumor settings such as CKD4/6 inhibitors and IDO1 inhibitors, and cellular therapy
approaches. While we have enthusiasm for the ongoing study of these agents, it is too early
to consider them as having practice-changing potential.
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Table 4. Future therapies and ongoing clinical trials.
Trial

Disease Setting

Comparator Arm

Treatment

Study Phase

Estimated Completion

Primary Endpoint(s)

NCT03937210
(COSMIC-313)

Previously untreated
advanced or mRCC

Cabozantinib-matched
placebo
+
Nivolumab
+
Ipilimumab

Cabozantinib
+
Nivolumab
+
Ipilimumab

Phase III

March 2025

PFS

NCT03873402
(CA209-8Y8)

Advanced RCC

N/A

Nivolumab
+
Ipilimumab

Phase III

March 2025

PFS, ORR

NCT03592472
(RENAVIV)

Locally advanced
unrespectable or mRCC

Pazopanib
+
placebo

Pazopanib
+
Abexinostat

Phase III

June 2022

PFS

NCT04987203

Advanced RCC

Tivozanib

Tivozanib
+
Nivolumab;

Phase III

Aug 2025

PFS

Phase III

Oct 2024

PFS

NCT02811861
(CLEAR)

Advanced RCC

Sunitinib

Arm A: Lenvatinib
+
Everolimus
Arm B: Lenvatinib
+ Pembrolizumab

NCT03729245

Untreated advanced RCC

Sunitinib
or
Cabozantinib

Bempegaldesleukin+
Nivolumab

Phase III

June 2024

ORR, OS

NCT04810078
(CheckMate-67T)

Advanced clear cell RCC

Intravenous Nivolumab

Subcutaneous
Nivolumab

Phase III

June 2026

Time-averaged serum conc.,
trough serum concentration at
steady state

NCT05239728

Clear cell RCC

Placebo
+
Pembrolizumab

Belzutifan
+
Pembrolizumab

Phase III

Jan 2030

DFS

NCT03873402

Advanced RCC

Nivolumab
+
Ipilimumab

Nivolumab

Phase III

March 2025

PFS, ORR
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Table 4. Cont.
Trial

Disease Setting

Comparator Arm

Treatment

Study Phase

Estimated Completion

Primary Endpoint(s)

Phase III

Dec 2034

DFS, OS

NCT03288532
(RAMPART)

Resected primary RCC at
high or intermediate
relapse risk

N/A

Arm A:
Active monitoring
Arm B: Durvalumab
Arm C: Durvalumab
+
Tremelimumab

NCT04394975

Advanced RCC

Sunitinib

Toripalimab
+
Axitinib

Phase III

June 2023

PFS

NCT03095040
(CONCEPT)

mRCC

Everolimus

Vorolanib
+
Everolimus

Phase III

Dec 2021

PFS

NCT04698213
(TIDE-A)

Untreated mRCC

N/A

Avelumab
+
Intermittent Axitinib

Phase II

Oct 2024

ORR

Phase II

August 2026

DLT, AE, ORR

Arm 1: Pembrolizumab
+
Belzutifan
+
Lenvatinib

NCT04976634
(MK-6848-012)

Solid tumors

Pembrolizumab
+
Lenvatinib

NCT03634540
(MK-6482-003)

Advanced clear cell RCC

N/A

Belzutifan
+
Cabozantinib

Phase II

August 2025

ORR

NCT04846920

Advanced clear cell RCC

N/A

Belzutifan

Phase I

July 2025

AE, DLT

PFS, progression-free survival; ORR, objective response rate; DLT, dose-limiting toxicity; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; AE, adverse events; OS, overall
survival; DFS, disease-free survival; mRCC, metastatic renal cell carcinoma.
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7. Conclusions
The management of clear cell RCC has undergone radical changes as we are furthering
our understanding of the mRCC disease process and its underlying biologic drivers. We
are witnessing a paradigm change in the approach to newly diagnosed metastatic disease.
Careful attention to tumor biology and clinicopathologic patient characteristics can inform
patient-centered decisions to either enter active surveillance or choose metastasis-directed
therapy without the immediate need for upfront systemic therapies and their associated toxicities. Front-line treatment now typically employs IO/IO or various IO/TKI combination
therapies. Although the landmark studies leading to each approval are similarly designed,
there are distinct features to each therapy that may allow for a personalized approach to
each patient accounting for comorbidities, patient values, and tumor characteristics. Ongoing studies identifying predictive biomarkers will provide clarity and provide objective
measures to guide treatment choice in this crowded treatment landscape and usher us
into an era of personalized medicine in mRCC. Integration of validated biomarkers into
prospective studies evaluating novel therapies will be essential to achieving this goal.
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